+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bullous Pemphigoid - Pipeline Review, H2 2019

  • ID: 4901374
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 120 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Alkahest Inc
  • Amgen Inc
  • Eli Lilly and Co
  • Genzyme Corp
  • iCo Therapeutics Inc
  • MORE
Bullous Pemphigoid - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Pipeline Review, H2 2019, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 6, 2 and 4 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Alkahest Inc
  • Amgen Inc
  • Eli Lilly and Co
  • Genzyme Corp
  • iCo Therapeutics Inc
  • MORE
Introduction
Report Coverage
Bullous Pemphigoid - Overview
Bullous Pemphigoid - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bullous Pemphigoid - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bullous Pemphigoid - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alkahest Inc
Amgen Inc
Eli Lilly and Co
Genzyme Corp
iCo Therapeutics Inc
Immungenetics AG
Regeneron Pharmaceuticals Inc
Sangamo Therapeutics Inc
viDA Therapeutics Inc
Bullous Pemphigoid - Drug Profiles
Bullous Pemphigoid - Dormant Projects
Bullous Pemphigoid - Discontinued Products
Bullous Pemphigoid - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Bullous Pemphigoid, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bullous Pemphigoid - Pipeline by Akari Therapeutics Plc, H2 2019
Bullous Pemphigoid - Pipeline by Alkahest Inc, H2 2019
Bullous Pemphigoid - Pipeline by Amgen Inc, H2 2019
Bullous Pemphigoid - Pipeline by Eli Lilly and Co, H2 2019
Bullous Pemphigoid - Pipeline by Genzyme Corp, H2 2019
Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc, H2 2019
Bullous Pemphigoid - Pipeline by Immungenetics AG, H2 2019
Bullous Pemphigoid - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Bullous Pemphigoid - Pipeline by Sangamo Therapeutics Inc, H2 2019
Bullous Pemphigoid - Pipeline by viDA Therapeutics Inc, H2 2019
Bullous Pemphigoid - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Bullous Pemphigoid, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Akari Therapeutics Plc
  • Alkahest Inc
  • Amgen Inc
  • Eli Lilly and Co
  • Genzyme Corp
  • iCo Therapeutics Inc
  • Immungenetics AG
  • Regeneron Pharmaceuticals Inc
  • Sangamo Therapeutics Inc
  • viDA Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll